For the treatment of a runny nose, drugs that eliminate not only the symptoms, but also affect the cause of the disease are very helpful. These products include the nasal spray "Genferon Light". It stimulates the immune response, strengthens the body's defense system, due to which the therapeutic effect is noticeable already in the first days of use.
"Genferon Light": description and pharmacodynamics
The drug is available in the form of a nasal spray (for the nose), drops (for the eyes) and suppositories (administered rectally or vaginally). The composition includes the active component interferon, which is of the alpha-2b type. Another active substance is taurine. The composition also contains additional components - water, sodium and potassium chlorides, polycarbonate, glycerin and others.
Interferon is produced by synthesis by bacteria using genetic engineering technology. It has a complex effect on the body:
- strengthening the immune system;
- antiviral;
- antibacterial.
The drug triggers an immune response, enhances the cellular reactions of the immune system, making it better able to cope with viruses and other intracellular parasites. This is possible due to increased activity of various cells, including T-killers.
Taurine helps eliminate pathological foci with inflammatory processes. It is a strong antioxidant that destroys free radicals - dangerous molecules that destroy body cells. Taurine also helps interferon to be better absorbed, which enhances its therapeutic effect.
You can store the drug in a cool place in the temperature range from 2 to 8 degrees Celsius, for example, in the refrigerator. Should be protected from direct sunlight and should not be accessible to children. The shelf life of the product is 2 years from the date of production, subject to storage conditions.
Genferon Light drops naz 10 thousand IU/ml+0.8 mg/ml 10 ml x1
Genferon Light drops naz 10 thousand IU/ml+0.8 mg/ml 10 ml x1 ATX code: L03A (Immunostimulants)
Active substances
taurine Rec.INN registered by WHO interferon alfa-2b USAN accepted for use in the USA
Dosage form
GENFERON® LIGHT
nasal drops 10,000 IU+0.8 mg/1 ml: vial. 10 ml with dropper nozzlereg. No.: LP-002309 dated 11/25/13 - Valid
Release form, packaging and composition of Genferon Light
Nasal drops are transparent, colorless or light yellow.
1 ml
interferon alpha-2b human recombinant* 10,000 IU
taurine 0.8 mg
* the substance “Human recombinant interferon alpha-2b (rhIFN-α2b)” includes excipients: sodium chloride, sodium acetate trihydrate, glacial acetic acid, water for injection.
Excipients: disodium edetate dihydrate - 0.02 mg, glycerol - 7 mg, dextran 35-45 thousand - 2.4 mg, polysorbate 80 - 1 mg, sodium chloride - 0.8 mg, potassium chloride - 0.02 mg, sodium hydrogen phosphate - 0.115 mg, sodium dihydrogen phosphate - 0.02 mg, water for injection - up to 1 ml.
10 ml - dark glass bottles (1) complete with a dropper attachment - cardboard packs.
Clinical and pharmacological group: Interferon. Immunomodulatory drug with antiviral effect Pharmacotherapeutic group: Immunomodulatory agent
pharmachologic effect
The drug Genferon Light, nasal drops, has antiviral, immunomodulatory, anti-inflammatory, antiproliferative, antibacterial effects, has local regenerating, membrane-stabilizing and antioxidant properties. Interferon alpha blocks the proliferation of viruses at the stage of synthesis of specific proteins and prevents infection of uninfected cells of the nasal mucosa, which is the site of pathogen invasion and the primary focus of inflammation during respiratory infections. The immunomodulatory effect is manifested by an increase in cell-mediated reactions of the immune system, which increases the effectiveness of the immune response against foreign agents. This is achieved through the activation of CD8+ T-killers, NK cells (natural killer cells), increased differentiation of B-lymphocytes and their production of antibodies, activation of the monocyte-macrophage system and phagocytosis, as well as increased expression of molecules of the main histocompatibility complex type 1, which increases the likelihood recognition of infected cells by cells of the immune system. Activation of leukocytes contained in all layers of the mucous membrane under the influence of interferon ensures their active participation in the elimination of pathological foci; in addition, due to the influence of interferon, the production of secretory immunoglobulin A is restored. The antibacterial effect is mediated by reactions of the immune system, enhanced by the iodine influence of interferon.
Taurine, which is part of the drug, normalizes metabolic processes in tissues, promotes regeneration and faster restoration of the nasal mucosa damaged by the pathological process.
Pharmacokinetics
When used intranasally, the drug Genferon Light, nasal drops, creates a high concentration of interferon at the site of infection and has a pronounced local antiviral and immunostimulating effect. Systemic absorption of the drug is insignificant; with intranasal administration, recombinant human interferon alpha-2b is detected in small quantities in the lung tissue and blood. In the body, biotransformation occurs predominantly in the kidneys with a T1/2 of 5.1 hours. A small amount of the drug entering the systemic circulation has a systemic immunomodulatory effect.
Indications for the drug Genferon Light
treatment of influenza and other acute respiratory viral infections in children aged 29 days to 14 years. ICD-10 codes
ICD-10 code Indication
J06.9 Acute upper respiratory tract infection, unspecified
J10 Influenza caused by an identified influenza virus
Dosage regimen
At the first signs of the disease, Genferon Light is instilled into the nose for 5 days.
Children from 29 days to 11 months 29 days - 1 drop in each nasal passage 5 times a day (single dose 1,000 IU, daily dose 5,000 IU).
Children from 1 to 3 years old - 2 drops in each nasal passage 3-4 times a day (single dose 2,000 IU; daily dose 6,000-8,000 IU).
Children from 3 to 14 years old - 2 drops in each nasal passage 4-5 times a day (single dose 2,000 IU, daily dose - 8,000-10,000 IU).
Side effect
Local allergic reactions (burning sensation, itching) are possible. These phenomena are reversible and disappear on their own within 72 hours after stopping the use of the drug. Continuation of treatment is possible only after consultation with a doctor.
Contraindications for use
hypersensitivity to interferon alfa-2b or other components of the drug, newborns from 0 to 28 days (due to the lack of clinical data).
Use during pregnancy and breastfeeding
Not used because the drug is indicated for use in children aged 29 days to 14 years.
Use in children Contraindicated in newborns up to 28 days.
special instructions
After instillation, it is recommended to massage the wings of the nose with your fingers for several minutes to evenly distribute the drug in the nasal cavity.
Impact on the ability to drive vehicles and operate machinery
The effect of the drug Genferon Light on the performance of potentially hazardous activities that require special attention and quick reactions (driving vehicles, machinery, etc.) has not been studied.
Overdose
Cases of overdose of the drug Genferon Light have not been registered to date.
Drug interactions
The simultaneous use of intranasal vasoconstrictor drugs is not recommended, as this causes additional dryness of the nasal mucosa.
Storage conditions for Genferon Light
In a dry place, protected from light, at a temperature of 2 to 8°C.
Within the stated expiration date, patients can store the drug after opening for 7 weeks at a temperature of 2 to 8°C.
Keep out of the reach of children.
Shelf life of Genferon Light Shelf life - 2 years.
Terms of sale Without a prescription.
Side effects and overdose
Side effects are rare. They are mainly associated with allergic reactions and bloody nasal discharge. Such reactions in most cases are not complicated by long-term consequences, pass quickly enough, and therefore do not require additional treatment.
To date, cases of overdose have not been described. Taking the drug is safe if the dosages specified in the instructions are followed. You can take the nasal spray during pregnancy, as well as during breastfeeding.
Nasal spray "Genferon Light": instructions for use
The spray is intended for intranasal use, i.e. insertion into the nose. One dose corresponds to one short press on the bottle cap. During the first 5 days, the spray is administered 1 dose into each nasal sinus up to 3 times a day.
If there has been contact with a patient with a respiratory infection or in case of hypothermia, the spray is administered according to the same scheme 2 times a day, with the duration of therapy ranging from 5 to 7 days. After this, take a break and, if necessary, repeat the preventive course.
Using the spray is quite simple:
- Remove the protective cap.
- Blow your nose.
- Insert the cap into the nose and press for a second.
- During use, hold the bottle only vertically.
- After this, put the protective cap back on.
It is better to apply the spray individually. To avoid spreading the infection, it is not recommended to pass it on to others.
Genferon light nasal spray 50000IU+1mg/dose 100 doses No. 1
Name
Genferon light.
Release forms
Nasal spray.
INN
Interferon alpha-2b + taurine.
FTG
Immunomodulatory agent.
Compound
1 dose of the drug contains: active substances: human recombinant interferon alpha-2b 50,000 IU taurine 1 mg. excipients: disodium edetate dihydrate 0.02 mg, glycerin 7.0 mg, dextran 40000 2.4 mg, polysorbate 80 1.0 mg, sodium chloride 0.8 mg, potassium chloride 0.02 mg, sodium hydrogen phosphate dodecahydrate 0.115 mg , potassium dihydrogen phosphate 0.02 mg, peppermint oil 0.01 mg, methyl parahydroxybenzoate 0.02 mg, sufficient amount of water for injection. * The composition of the substance “Interferon alpha-2b human recombinant” includes excipients in accordance with the FSP of JSC “BIOCAD”: sodium chloride, sodium acetate trihydrate, acetic acid (glacial), water for injection.
Description
Transparent colorless or light yellow liquid, without visible mechanical inclusions.
Pharmacotherapeutic group
Immunomodulatory agents, interferons. ATX code: L03AB05
Pharmacological properties
Pharmacodynamics
Immunobiological properties. Recombinant human interferon alpha-2b, which is the active component of the drug Genferon® Light nasal spray, has antiviral, immunomodulatory, indirect antibacterial and antiproliferative properties. The antiviral effect of interferon alpha-2b is mediated by the activation of a number of intracellular enzymes that inhibit viral replication. The immunomodulatory effect is manifested primarily by an increase in cell-mediated reactions of the immune system. Interferon increases the cytotoxicity of T-lymphocytes, natural killer cells, the phagocytic activity of macrophages, promotes the differentiation of T-helper cells, and protects T-cells from apoptosis. The immunomodulatory effect of interferon is also due to the influence on the production of a number of cytokines (interleukin, interferon gamma). All these effects of interferon can mediate its therapeutic activity. Taurine is a natural metabolic product of sulfur-containing amino acids: cysteine, cysteamine, methionine. Taurine has osmoregulatory and membrane protective properties, has a positive effect on the phospholipid composition of cell membranes, and normalizes the exchange of calcium and potassium ions in cells.
Pharmacokinetics
When administered intranasally, due to the high concentration at the site of infection, a pronounced local antiviral and immunostimulating effect is achieved. Pharmacokinetic studies have not been conducted due to the low bioavailability of recombinant protein preparations when administered intranasally, as a result of which the concentration of the active substance achieved in the blood when using the drug in recommended doses is significantly lower than the detection limit and has no clinical significance.
Indications for use
Prevention and treatment of influenza and ARVI in adults.
Directions for use and doses
The drug is administered intranasally by aerosol administration of 1 dose (1 dose = 1 short press on the dispenser). At the first signs of the disease, GENFERON® LITE is administered intranasally for 5 days, one dose (one press on the dispenser) into each nasal passage 3 times a day (one dose is approximately 50,000 IU of interferon alpha, the daily dose should not exceed 500,000 IU). In case of contact with a patient with acute respiratory viral infection and/or hypothermia, the drug is administered according to the indicated regimen 2 times a day for 5-7 days. If necessary, preventive courses are repeated. Instructions for using the spray: 1. Remove the protective cap. 2. Before using for the first time, press the dispenser several times until a thin stream appears. 3. When using, keep the bottle upright. 4. Inject the drug by pressing the dispenser once into each nasal passage in turn. 5. After use, close the dispenser with the protective cap. To avoid the spread of infection, individual use is recommended.
Side effect
In isolated cases, the use of GENFERON® LITE nasal spray may cause the development of side effects in the form of local allergic reactions and bleeding from the nose. As a rule, these reactions are mild and do not require additional drug therapy.
Contraindications
Hypersensitivity to interferon alfa-2b or other components of the drug. Children under 18 years of age.
Carefully
Should be prescribed with caution to patients suffering from nosebleeds.
Use during pregnancy and lactation
There are no data on the safety of use during pregnancy and lactation.
Use in special patient groups
Patients with impaired liver or kidney function, as well as elderly patients, do not require dosage adjustment.
Overdose
No cases of overdose of the drug GENFERON® LITE have been reported.
Precautionary measures
The drug should not be used if the integrity and labeling of the packaging is damaged, if the physical properties (color and transparency of the liquid) change, or after the expiration date.
Interaction with other drugs
Not noted.
Impact on the ability to drive vehicles and machinery
Does not affect.
Release form
100 doses in a dark glass bottle, sealed with a dispenser with a protective cap. 1 bottle with instructions for use in a cardboard pack.
Storage and transportation conditions
Store and transport in a place protected from moisture and light at a temperature of 2 to 8 °C. Keep out of the reach of children.
Best before date
2 years. Do not use after the expiration date stated on the package.
Conditions for dispensing from pharmacies
Over the counter.
Buy Genferon light spray called dosage. 50000 IU + 1 mg/d, 100 d in bottle with dispenser and bottle in pack No. 1 in the pharmacy
Price for Genferon light spray called dosage. 50000 IU + 1 mg/d, 100 d in bottle with dispenser and cap in pack No. 1
Instructions for use for Genferon light spray called dosage 50000ME+1 mg/d 100 d in bottle with dispenser and cap in pack No. 1
Special instructions and drug interactions
In case of long-term observation of side effects, stop taking the drug and consult a doctor for advice. The nasal spray can be used in combination with various drugs, with the exception of intranasal vasoconstrictor drugs. In combination with Geneferon Light, they promote rapid drying of the nasal mucosa, which can have a bad effect on its condition.
The spray is safe for health, does not reduce the reaction, does not lead to drowsiness and does not affect performance. Therefore, it can be used by drivers and operators of moving machinery.
